Takeda adds one more late-stage treatment to its growing roster of celiac drugs

Whatever happens with Takeda’s determined campaign to tackle celiac disease from all sides, no one will ever be able to fault them for a lack of dedication to the cause.

This morning, the global player joined hands with Zedira and Dr. Falk Pharma GmbH on a Phase IIb celiac drug dubbed ZED1227/TAK-227, giving Takeda dibs on the big US market plus a string of countries outside Europe.